Pfizer Gets FDA Panel’s Backing in RSV Vaccine Race


An advisory committee to the US health regulator has recommended Pfizer’s respiratory syncytial virus (RSV) vaccine for older adults, voting 7-4 in favor of its efficacy and safety in preventing lower respiratory tract disease caused by RSV in people aged 60 and above. However, some members expressed concern over insufficient efficacy data for adults aged 80 and above. GSK, which is also developing an RSV vaccine, will face scrutiny from an FDA panel. The virus kills around 14,000 older adults in the US each year, with analysts estimating the market for approved vaccines at between $5 and $10 billion. To read the full article, click here. For more information on COVID-19, click here.

Comments are closed.

Skip to toolbar